Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT05395052
- Locations
- 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸UCLA Division of Hematology-Oncology, Los Angeles, California, United States
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 20
- Registration Number
- NCT05385705
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
HPV16 E6 TCR T Cells for Cervical Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- TCRCure Biopharma Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05357027
- Locations
- 🇨🇳
Xiaochun Cheng, Chongqing, Chongqing, China
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Liu Tian
- Target Recruit Count
- 60
- Registration Number
- NCT05339217
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Century Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05336409
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Diego, Moores Cancer Center, San Diego, California, United States
Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05262686
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 10
- Registration Number
- NCT05141474
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Corregene Biotechnology Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05122221
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT04952155
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT04893915
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.